Anti-IgE antibody (Omalizumab)

Abstract

This article discusses the mechanism of action, indications, administration methods, and side effects of omalizumab, an anti-IgE antibody, with a focus on pediatric bronchial asthma. The indications and ages for omalizumab in the treatment of chronic idiopathic urticaria and seasonal allergic rhinitis are also addressed. Omalizumab has been attracting attention as a promising treatment for severe or refractory pediatric bronchial asthma. By discussing important considerations and evaluation points when introducing omalizumab, we aim to provide useful guidance for its appropriate use in clinical practice.